Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer's Record-Breaking $2.3 Bil. Settlement With U.S. Attorney Imposes New Restrictions on Corporate Behavior

Executive Summary

Pfizer's $2.3 billion settlement with the U.S. Department of Justice is unprecedented in size and scope, resolving allegations of off-label marketing of four drugs and kickbacks to health care providers involving nine other drugs. Moreover, the deal includes the largest criminal fine ever imposed by the U.S. government in any matter
Advertisement

Related Content

Abbott Avoids Compliance Requirements In Kos Off-Label Marketing Settlement
Pfizer Says Government Investigations Must Be Avoided, Since "There Is No Way Of Winning" Once They Start
DOJ To Expand Use Of False Claims Act To Manufacturing And AER Violations
Health Care Fraud Investigations Bedevil Pharma Industry: If You're Not Under Investigation, It's Only Because You've Recently Settled
Lilly Outside "Faculty" Is Headed By 22 Physicians Receiving $50,000 Or More
Allergan Freedom From Expression Suit Challenges REMS, Off-Label Powers
Lessons From The Pfizer Off-Label Settlement: Compliance Programs Not Enough To Demonstrate Integrity, DOJ Says
Pfizer Settlement Means New Oversight; Does It Mean A New Marketing Plan?
Bextra $2.3 Bil. Charge For Pfizer Off-Label Settlement Mars Pre-Wyeth Earnings Report
Lilly’s Zyprexa Off-Label Settlement: Record Fine, Routine Compliance Deal

Topics

Advertisement
UsernamePublicRestriction

Register

PS051461

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel